The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours.

ABSTRACT:

Background

Use of cyclin D1 (CCND1) gene amplification as a breast cancer biomarker has been hampered by conflicting assessments of the relationship between cyclin D1 protein levels and patient survival. Here, we aimed to clarify its prognostic and treatment predictive potential through comprehensive long-term survival analyses.

Methods

CCND1 amplification was assessed using SNP arrays from two cohorts of 1965 and 340 patients with matching gene expression array and clinical follow-up data of over 15 years. Kaplan-Meier and multivariable Cox regression analyses were used to determine survival differences between CCND1 amplified vs. non-amplified tumours in clinically relevant patient sets, within PAM50 subtypes and within treatment-specific subgroups. Boxplots and differenti

SUBMITTER: Lundberg A 

PROVIDER: S-EPMC6394106 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature